[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gang Hou\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648381","randomized-controlled-trial-of-multi-patient-ct-derived-digital-twin-anatomical-variability-training-to-shorten-the-clinical-learning-curve-for-bronchoscopy-100648381",false,"NCT07718451","Randomized Controlled Trial of Multi-Patient CT-Derived Digital Twin Anatomical Variability Training to Shorten the Clinical Learning Curve for Bronchoscopy","Inclusion Criteria:\n\nTrainee Participants:\n\n1. Residents, fellows, or specialty trainees in pulmonary medicine, critical care medicine, thoracic surgery, anesthesiology, or related specialties whose training programs require flexible bronchoscopy training.\n2. Previously performed ≤5 flexible bronchoscopies as primary operator.\n3. No prior formal bronchoscopy simulation training course experience.\n4. Able and willing to provide written informed consent and permit use of training logs, procedural videos, Ontario Bronchoscopy Assessment Tool (OBAT) scores, and clinical learning curve data for research purposes.\n\nPatient Participants:\n\n1. Age ≥18 years.\n2. Scheduled to undergo elective low-risk or low-to-moderate-risk diagnostic flexible bronchoscopy.\n3. Clinically suitable for supervised novice-performed airway inspection, bronchoalveolar lavage, simple brushing, or other low-risk sampling procedures considered safe by the supervising bronchoscopist.\n4. Able to understand and provide written informed consent and willing to complete pre-procedure anxiety and post-procedure experience questionnaires.\n\nExclusion Criteria:\n\nTrainee Participants:\n\n1. Previously performed \\>5 flexible bronchoscopies or previously completed a structured bronchoscopy simulation training program.\n2. Planned departure from the training program during the study period or anticipated inability to complete follow-up through at least clinical cases 1-30.\n3. Unable to participate in simulation training or unwilling to permit procedural video recording.\n4. Significant additional bronchoscopy training exposure outside the study protocol; such cases may not necessarily be excluded but will be documented and addressed in sensitivity analyses.\n\nPatient Participants:\n\n1. Emergency bronchoscopy, intubated intensive care unit patients, severe hypoxemia, or significant hemodynamic instability.\n2. Therapeutic bronchoscopy, complex central airway stenosis, high bleeding risk, procedures requiring advanced interventional techniques, or cases considered unsuitable for novice participation.\n3. Complex sampling procedures such as EBUS-TBNA, transbronchial lung biopsy, or cryobiopsy will not be included in the primary endpoint case set and may be analyzed separately as exploratory subgroups or in future studies.\n4. Refusal of trainee participation or refusal of procedural recording and\u002For questionnaire completion.","ALL","18 Years","75 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to determine whether multi-patient CT-derived digital twin anatomical variability training can shorten the early clinical learning curve of novice bronchoscopists compared with conventional anatomically uniform bronchoscopy simulation training.",[26,27,28],"Bronchoscopy","Learning Curves and Outcomes of Simulation-based Training","Learning Curve",[30,31],"bronchoscopy","learning curve","RECRUITING","2026-07-17",{"date":35,"type":36},"2026-07-22","ACTUAL",{"date":38,"type":36},"2026-05-20",{"date":40,"type":20},"2027-12-30",{"name":42,"class":43},"Gang Hou","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100618533","phase-1-first-in-human-expanded-cohort-study-of-intrapleural-administration-of-toluenesulfonamide-in-patients-with-malignant-pleural-effusion-100618533","NCT07332858","First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion","Inclusion Criteria:\n\n1. Age between 18 and 75 years (inclusive) at the time of signing the informed consent form.\n2. Histologically or cytologically confirmed malignant pleural effusion, with the primary tumor diagnosed as non-small cell lung cancer (NSCLC).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of at least 3 months.\n4. Presence of dyspnea symptoms.\n5. No prior local thoracic treatment within 1 month before enrollment, including intrapleural drug administration or thoracic radiotherapy (diagnostic thoracentesis is permitted).\n6. Except for the subject's current stable systemic anti-tumor therapy, any other ongoing tumor-related treatments must be suspended or discontinued after evaluation by the investigator to ensure they do not interfere with the assessment of PTS treatment.\n7. Fully understands the study objectives and procedures, agrees to participate in the study, and provides written informed consent.\n\nExclusion Criteria:\n\n1. History of allergy or hypersensitivity to PTS or any of its excipients.\n2. Presence of uncontrolled intrapleural infection or severe loculated pleural effusion that is difficult to manage.\n3. Participation in another interventional clinical study within 3 months prior to enrollment (diagnostic studies are excluded).\n4. Severe organ dysfunction, including but not limited to coagulation disorders, congestive heart failure, malignant arrhythmias, coronary artery disease requiring long-term medication, valvular heart disease, myocardial infarction, or refractory hypertension; severe cardiac, hepatic, or renal insufficiency, or active bleeding or thrombotic risk.\n5. Presence of uncontrolled infectious wounds.\n6. Pregnant or breastfeeding women.\n7. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.\n8. Criteria for withdrawal from the study.",{"count":52,"type":20},105,[54,55],"PHASE1","PHASE2","This study aims to evaluate the safety of intrapleural injection of TolueneSulfonamide in patients with malignant pleural effusion and to explore its potential effectiveness.",[58,59],"Malignant Pleural Effusions (Mpe)","Non Small Cell Lung Cancer",[61,62],"Malignant Pleural Effusion","Para-toluenesulfonamide","2026-05-14",{"date":65,"type":36},"2026-05-15",{"date":67,"type":36},"2026-04-24",{"date":69,"type":20},"2028-10-30",{"name":42,"class":43},""]